vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.

TRANSCONTINENTAL REALTY INVESTORS INC is the larger business by last-quarter revenue ($12.1M vs $6.6M, roughly 1.8× Lineage Cell Therapeutics, Inc.). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs 12.9%, a 55.9% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 2.3%). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 0.7%).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.

LCTX vs TCI — Head-to-Head

Bigger by revenue
TCI
TCI
1.8× larger
TCI
$12.1M
$6.6M
LCTX
Growing faster (revenue YoY)
LCTX
LCTX
+128.1% gap
LCTX
130.4%
2.3%
TCI
Higher net margin
TCI
TCI
55.9% more per $
TCI
68.8%
12.9%
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
0.7%
TCI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LCTX
LCTX
TCI
TCI
Revenue
$6.6M
$12.1M
Net Profit
$851.0K
$8.3M
Gross Margin
Operating Margin
-99.1%
-28.9%
Net Margin
12.9%
68.8%
Revenue YoY
130.4%
2.3%
Net Profit YoY
126.0%
7577.8%
EPS (diluted)
$0.00
$0.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
TCI
TCI
Q4 25
$6.6M
$12.1M
Q3 25
$3.7M
$12.8M
Q2 25
$2.8M
$12.2M
Q1 25
$1.5M
$12.0M
Q4 24
$2.9M
$11.8M
Q3 24
$3.8M
$11.6M
Q2 24
$1.4M
$11.8M
Q1 24
$1.4M
$11.9M
Net Profit
LCTX
LCTX
TCI
TCI
Q4 25
$851.0K
$8.3M
Q3 25
$-29.8M
$724.0K
Q2 25
$-30.5M
$169.0K
Q1 25
$-4.1M
$4.6M
Q4 24
$-3.3M
$108.0K
Q3 24
$-3.0M
$1.7M
Q2 24
$-5.8M
$1.5M
Q1 24
$-6.5M
$2.5M
Gross Margin
LCTX
LCTX
TCI
TCI
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
LCTX
LCTX
TCI
TCI
Q4 25
-99.1%
-28.9%
Q3 25
-102.9%
-10.9%
Q2 25
-715.4%
-6.8%
Q1 25
-433.1%
-5.3%
Q4 24
-178.2%
-14.3%
Q3 24
-101.6%
-14.4%
Q2 24
-416.7%
-9.2%
Q1 24
-461.3%
-11.2%
Net Margin
LCTX
LCTX
TCI
TCI
Q4 25
12.9%
68.8%
Q3 25
-809.0%
5.6%
Q2 25
-1101.8%
1.4%
Q1 25
-275.6%
38.5%
Q4 24
-114.1%
0.9%
Q3 24
-80.3%
14.7%
Q2 24
-409.1%
12.7%
Q1 24
-453.0%
21.4%
EPS (diluted)
LCTX
LCTX
TCI
TCI
Q4 25
$0.00
$0.97
Q3 25
$-0.13
$0.08
Q2 25
$-0.13
$0.02
Q1 25
$-0.02
$0.53
Q4 24
$0.00
$0.01
Q3 24
$-0.02
$0.20
Q2 24
$-0.03
$0.17
Q1 24
$-0.04
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
TCI
TCI
Cash + ST InvestmentsLiquidity on hand
$55.8M
$89.0M
Total DebtLower is stronger
$210.8M
Stockholders' EquityBook value
$44.5M
$846.7M
Total Assets
$112.6M
$1.1B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
TCI
TCI
Q4 25
$55.8M
$89.0M
Q3 25
$40.5M
$82.7M
Q2 25
$42.3M
$73.5M
Q1 25
$47.9M
$88.6M
Q4 24
$47.8M
$99.7M
Q3 24
$32.7M
$131.6M
Q2 24
$38.5M
$127.5M
Q1 24
$43.6M
$130.8M
Total Debt
LCTX
LCTX
TCI
TCI
Q4 25
$210.8M
Q3 25
$223.5M
Q2 25
$212.4M
Q1 25
$198.2M
Q4 24
$181.9M
Q3 24
$180.3M
Q2 24
$177.4M
Q1 24
$178.3M
Stockholders' Equity
LCTX
LCTX
TCI
TCI
Q4 25
$44.5M
$846.7M
Q3 25
$22.0M
$838.4M
Q2 25
$48.4M
$837.7M
Q1 25
$79.0M
$837.3M
Q4 24
$78.4M
$832.3M
Q3 24
$66.2M
$832.2M
Q2 24
$68.3M
$830.4M
Q1 24
$72.4M
$828.9M
Total Assets
LCTX
LCTX
TCI
TCI
Q4 25
$112.6M
$1.1B
Q3 25
$89.6M
$1.1B
Q2 25
$90.8M
$1.1B
Q1 25
$111.8M
$1.1B
Q4 24
$113.2M
$1.1B
Q3 24
$96.6M
$1.1B
Q2 24
$102.8M
$1.0B
Q1 24
$108.5M
$1.0B
Debt / Equity
LCTX
LCTX
TCI
TCI
Q4 25
0.25×
Q3 25
0.27×
Q2 25
0.25×
Q1 25
0.24×
Q4 24
0.22×
Q3 24
0.22×
Q2 24
0.21×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
TCI
TCI
Operating Cash FlowLast quarter
$-4.9M
$-2.9M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-79.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
-5.73×
-0.35×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
TCI
TCI
Q4 25
$-4.9M
$-2.9M
Q3 25
$-3.6M
$8.2M
Q2 25
$-5.5M
$-2.9M
Q1 25
$-4.9M
$-7.4M
Q4 24
$-6.3M
$1.3M
Q3 24
$-5.8M
$13.7M
Q2 24
$-5.2M
$-511.0K
Q1 24
$-5.8M
$3.9M
Free Cash Flow
LCTX
LCTX
TCI
TCI
Q4 25
$-5.3M
Q3 25
$-3.6M
Q2 25
$-5.6M
Q1 25
$-5.0M
Q4 24
$-6.7M
Q3 24
$-5.9M
Q2 24
$-5.2M
Q1 24
$-5.8M
FCF Margin
LCTX
LCTX
TCI
TCI
Q4 25
-79.9%
Q3 25
-98.6%
Q2 25
-200.8%
Q1 25
-331.8%
Q4 24
-234.0%
Q3 24
-156.1%
Q2 24
-371.2%
Q1 24
-403.1%
Capex Intensity
LCTX
LCTX
TCI
TCI
Q4 25
6.0%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
6.5%
Q4 24
12.7%
Q3 24
3.0%
Q2 24
3.6%
Q1 24
2.6%
Cash Conversion
LCTX
LCTX
TCI
TCI
Q4 25
-5.73×
-0.35×
Q3 25
11.28×
Q2 25
-17.24×
Q1 25
-1.61×
Q4 24
12.13×
Q3 24
8.03×
Q2 24
-0.34×
Q1 24
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

TCI
TCI

Segment breakdown not available.

Related Comparisons